Ruthanne Williams Roussel submits:

As many will know by now, an FDA briefing panel July 15 recommended against approval of Vivus’ (VVUS) obesity drug candidate Qnexa by a vote of 10 to 6. This was originally announced as a vote of 9 to 7, but a new electronic voting system was in use, and it must have been a little confusing, because one panelist later claimed that they had unintentionally voted "Yes" for approval instead of "No" against. (Insert "Jim, I’m a doctor, not an electronic voter!" joke here.)

The main concerns cited about Qnexa were:

Complete Story »

Further information:

Article source

Related posts:

1. Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity
2. Allergan Gets FDA Approval: Botox Has a Medical Use?
3. Orexigen Receives Bad News From FDA About Contrave
4. Pfizer’s Prevnar 13 Gains FDA Approval
5. 5-Days-After-Sex Pill Gets FDA Panel Nod